334 results on '"Branagan, A. R."'
Search Results
52. Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series
53. Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
54. A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
55. Prospective Study of Acalabrutinib with Rituximab in Patients with Symptomatic Anti-MAG Mediated IgM Peripheral Neuropathy
56. Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia
57. Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth
58. Novel Agents in the Treatment of Waldenström's Macroglobulinemia
59. Genetic Linkage of FcgγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy
60. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice
61. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
62. Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.
63. Cell‐free DNA analysis for detection ofMYD88 L265PandCXCR4 S338Xmutations in W aldenström macroglobulinemia
64. CD52 Is Expressed on Human Mast Cells and Is a Potential Therapeutic Target in Waldenström's Macroglobulinemia and Mast Cell Disorders
65. Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia
66. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia
67. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
68. Clinical application of genomics in Waldenström macroglobulinemia
69. Extending Dosing Intervals of Denosumab As a Maintenance Strategy in Multiple Myeloma: A Real-World Experience at a Large Academic Cancer Center
70. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID‐19 Pandemic
71. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies
72. CHOP plus Rituximab Therapy in Waldenström's Macroglobulinemia
73. CD5, CD10, and CD23 Expression in Waldenström's Macroglobulinemia
74. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma.
75. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
76. Consensus statement on the management of Waldenström macroglobulinemia patients during the COVID-19 pandemic
77. Hepatitis C Viral Infection Is Not Associated With Waldenströmʼs Macroglobulinemia
78. Mast cells in Waldenstromʼs macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling
79. Characterization of familial Waldenströmʼs macroglobulinemia
80. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
81. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic
82. Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenströmʼs Macroglobulinemia
83. Extended rituximab therapy in Waldenströmʼs macroglobulinemia
84. Clinical Responses to Sildenafil in Waldenstromʼs Macroglobulinemia
85. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstromʼs macroglobulinemia
86. Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
87. Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
88. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
89. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
90. A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
91. Genomic landscape of Waldenström's macroglobulinemia
92. Updates and rationale of clinical trials in multiple myeloma
93. Cell‐free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia.
94. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial
95. Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders
96. Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice
97. Humanized Mouse Model of Myeloma Reveals Clinically Occult Genomic Changes in Primary Tumor Cells
98. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia
99. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
100. Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.